 |
9 Diseases |  |
32 Trials |
|
32 Trials |  |
762 News |  |
| «12345678910» |
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) (clinicaltrials.gov) - Jun 28, 2016
P2, N=160, Recruiting, Sponsor: Forest Laboratories
Trial primary completion date: Jun 2017 --> Mar 2018
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P3 trial: A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation (clinicaltrials.gov) - Jun 22, 2016
P3, N=170, Not yet recruiting, Sponsor: Astellas Pharma Inc
- ||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion: Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - Jun 16, 2016
P3, N=500, Completed, Sponsor: Astellas Pharma Inc
Trial primary completion date: Jun 2017 --> Mar 2018 Active, not recruiting --> Completed
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment closed: Clinical Comparison of 27+ (clinicaltrials.gov) - Jun 9, 2016
P=N/A, N=137, Active, not recruiting, Sponsor: Alcon Research
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Clinical Comparison of 27+ (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=160, Recruiting, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> May 2016
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (clinicaltrials.gov) - Mar 23, 2016
P2, N=254, Completed, Sponsor: Forest Laboratories
Trial primary completion date: Aug 2016 --> May 2016 Active, not recruiting --> Completed
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, Enrollment change: Multipolar Mapping and Atrial Arrhythmias (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=5, Completed, Sponsor: Angelo Biviano
Active, not recruiting --> Completed Recruiting --> Completed | N=40 --> 5
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
FDA event, Enrollment change: CONFIRM: Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps (clinicaltrials.gov) - Mar 11, 2016
P=N/A, N=78, Completed, Sponsor: Virginia Commonwealth University
Recruiting --> Completed | N=40 --> 5 N=24 --> 78
- ||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, Trial primary completion date: Trial of Linaclotide in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Feb 12, 2016
P3, N=1223, Completed, Sponsor: Ironwood Pharmaceuticals, Inc.
N=24 --> 78 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Aug 2015
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Linzess DR (linaclotide DR) / Ironwood Pharma, AbbVie
Enrollment open: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - Jan 15, 2016
P2, N=520, Recruiting, Sponsor: Ironwood Pharmaceuticals, Inc.
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Aug 2015 Not yet recruiting --> Recruiting
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, Trial primary completion date: A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation (clinicaltrials.gov) - Dec 17, 2015
P2, N=383, Completed, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Oct 2015
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Biomarker, Enrollment open, Trial initiation date, Trial primary completion date: Caecal pH as a Biomarker for Irritable Bowel Syndrome (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=48, Recruiting, Sponsor: Wingate Institute of Neurogastroenterology
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Oct 2015 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Nov 2015 | Trial primary completion date: Mar 2016 --> Jun 2016
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS (clinicaltrials.gov) - Nov 27, 2015
P4, N=800, Recruiting, Sponsor: Forest Laboratories
Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Nov 2015 | Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - Nov 14, 2015
P3, N=500, Active, not recruiting, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Sep 2015
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Clinical Comparison of 27+ (clinicaltrials.gov) - Nov 8, 2015
P=N/A, N=160, Recruiting, Sponsor: Alcon Research
Trial primary completion date: Sep 2016 --> Sep 2015 Trial primary completion date: May 2016 --> Aug 2016
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) (clinicaltrials.gov) - Nov 3, 2015
P2, N=160, Recruiting, Sponsor: Forest Laboratories
Trial primary completion date: May 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: LIN-MD-63: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (clinicaltrials.gov) - Nov 3, 2015
P2, N=260, Recruiting, Sponsor: Forest Laboratories
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P4 trial: An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS (clinicaltrials.gov) - Oct 29, 2015
P4, N=800, Not yet recruiting, Sponsor: Forest Laboratories
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Efficacy of Linaclotide to Senna for CIC (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=70, Recruiting, Sponsor: TriHealth Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Jun 2016
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P2 trial: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) (clinicaltrials.gov) - Sep 24, 2015
P2, N=160, Not yet recruiting, Sponsor: Forest Laboratories
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Linzess DR (linaclotide DR) / Ironwood Pharma, AbbVie
New P2 trial: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - Sep 24, 2015
P2, N=520, Not yet recruiting, Sponsor: Ironwood Pharmaceuticals, Inc.
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P2 trial: LIN-MD-63: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (clinicaltrials.gov) - Sep 24, 2015
P2, N=260, Not yet recruiting, Sponsor: Forest Laboratories
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment closed: Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - Aug 1, 2015
P3, N=500, Active, not recruiting, Sponsor: Astellas Pharma Inc
Trial primary completion date: Sep 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: Clinical Comparison of 27+ (clinicaltrials.gov) - Jul 23, 2015
P=N/A, N=160, Recruiting, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers (clinicaltrials.gov) - Jun 25, 2015
P1, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2015 --> Mar 2018
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New trial: Clinical Comparison of 27+ (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=160, Not yet recruiting, Sponsor: Alcon Research
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P4 trial: Single-dose Linaclotide for Capsule Endoscopy Preparation (clinicaltrials.gov) - Jun 6, 2015
P4, N=30, Recruiting, Sponsor: University of Virginia
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment closed: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (clinicaltrials.gov) - Jun 4, 2015
P2, N=240, Active, not recruiting, Sponsor: Forest Laboratories
Trial primary completion date: Mar 2015 --> Mar 2018 Recruiting --> Active, not recruiting
- ||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, Enrollment change: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - May 27, 2015
P3, N=1722, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=800 --> 1722
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation (clinicaltrials.gov) - May 24, 2015
P2, N=350, Recruiting, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed | N=800 --> 1722 Not yet recruiting --> Recruiting
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P2 trial: A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation (clinicaltrials.gov) - Apr 25, 2015
P2, N=350, Not yet recruiting, Sponsor: Astellas Pharma Inc
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: Efficacy of Linaclotide to Senna for CIC (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=70, Recruiting, Sponsor: TriHealth Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Biomarker: Caecal pH as a Biomarker for Irritable Bowel Syndrome (clinicaltrials.gov) - Feb 10, 2015
P=N/A, N=48, Not yet recruiting, Sponsor: Wingate Institute of Neurogastroenterology
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment closed: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - Feb 6, 2015
P3, N=800, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - Jan 13, 2015
P3, N=800, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> May 2015
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P3 trial: Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - Dec 16, 2014
P3, N=480, Recruiting, Sponsor: Astellas Pharma Inc
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Review, Journal: Multipolar Mapping and Atrial Arrhythmias (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=40, Recruiting, Sponsor: Angelo Biviano
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P3 trial: Trial of Linaclotide in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Nov 14, 2014
P3, N=1200, Recruiting, Sponsor: Ironwood Pharmaceuticals, Inc.
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (clinicaltrials.gov) - Oct 31, 2014
P2, N=240, Recruiting, Sponsor: Forest Laboratories
Trial primary completion date: Dec 2014 --> May 2015 Not yet recruiting --> Recruiting
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P2 trial: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (clinicaltrials.gov) - Oct 22, 2014
P2, N=240, Not yet recruiting, Sponsor: Forest Laboratories
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment closed: Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers (clinicaltrials.gov) - Sep 15, 2014
P1, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Clinical: Efficacy of Linaclotide to Senna for CIC (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=70, Not yet recruiting, Sponsor: TriHealth Inc.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P1 trial: LIN-PK-01: A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically (clinicaltrials.gov) - Aug 19, 2014
P1, N=8, Recruiting, Sponsor: Forest Laboratories
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion: A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - Apr 28, 2014
P2, N=559, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
FDA event, Enrollment change: CONFIRM: Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=24, Completed, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed N=15 --> 24
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, FDA event: CONFIRM: Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=24, Completed, Sponsor: Virginia Commonwealth University
N=15 --> 24 Enrolling by invitation --> Completed
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Clinical: Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients (clinicaltrials.gov) - Mar 3, 2014
P=N/A, N=45, Recruiting, Sponsor: Georgia Regents University
- ||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion: Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating (clinicaltrials.gov) - Sep 29, 2013
P3, N=487, Completed, Sponsor: Forest Laboratories
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P1 trial: Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers (clinicaltrials.gov) - Sep 23, 2013
P1, N=18, Recruiting, Sponsor: Mayo Clinic
- |||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (clinicaltrials.gov) - Aug 18, 2013
P3, N=800, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting